Katherine Chan, MD, on the mechanism of action for detalimogene voraplasmid

In this video, Katherine Chan, MD, MPH, highlights the mechanism of action for detalimogene voraplasmid (EG-70), which is currently in phase 1/2 development for the treatment of patients with non–muscle invasive bladder cancer (NMIBC). Chan is the senior medical director at enGene and a urologist at the University of North Carolina, Chapel Hill.

Video Transcript:

Detalimogene is a novel investigational genetic medicine for patients with high-risk bladder cancer, specifically non–muscle invasive bladder cancer that's resistant to BCG. That's the focus of our pivotal study that's ongoing right now, called the LEGEND trial. The way that it works, essentially, it's a genetic medicine. It's delivered with a non-viral vector as a nanoparticle. The nanoparticle is instilled into the bladder within a solution. It's about a 50 mL solution that's placed into the patient's bladder with a 60-minute dwell time. What happens, mechanistically speaking, is that it stimulates the 2 arms of the immune system, both innate immunity as well as the adaptive immunity. As far as that's concerned, it stimulates a very potent anti-tumor cytokine called IL-12. It also stimulates the RIG-I pathway, which then activates the innate immune system. We see this as a “one-two punch” that is very effective in delivering anti-tumor toxicity locally to the bladder, while also minimizing adverse side effects.

This transcript was AI generated and edited by human editors for clarity.